Ashland (ASH) Q4 2024 earnings summary

Executive summary

• Q4 2024 sales rose 1% year-over-year to $522 million, with organic sales volumes up 4% and adjusted EBITDA up 68% to $124 million, driven by margin recovery, improved production volumes, and portfolio optimization.

• Adjusted EPS increased 207% to $1.26 per share, and net income was $16 million, reversing a prior-year loss.

• Fiscal 2024 sales declined 4% to $2.1 billion due to portfolio actions and softer pricing, but adjusted EBITDA remained flat at $459 million, reflecting a resilient portfolio.

• Portfolio optimization included the sale of the Nutraceuticals business, the start of the Avoca business exit, and further divestitures, reducing volatility and improving margins.

• All core business units showed strong margin recovery, with three out of four units delivering adjusted EBITDA margins in the high 20s.

Financial highlights

• Q4 adjusted EBITDA margin increased 950 basis points to 23.8%, and gross profit margin improved 940 basis points to 34.3%.

• Q4 operating income increased 414% to $72 million; adjusted EPS rose to $1.26.

• FY2024 ongoing free cash flow was $270 million, up 24% year-over-year, with a 59% conversion rate.

• Repurchased $150 million (~1.7 million shares) in Q4; $620 million remains under buyback authorization.

Outlook and guidance

• Fiscal 2025 guidance: sales of $1.90–$2.05 billion and adjusted EBITDA of $430–$470 million, reflecting demand recovery, productivity gains, and restructuring benefits.

• Baseline for 2025 adjusted for portfolio changes is $449 million EBITDA, with mid-single digit volume growth expected.

• Key headwinds include China slowdown, competitive intensity, and Avoca business erosion ($15 million impact).

• $30 million restructuring plan and $60 million manufacturing productivity program to deliver $20 million in FY25 cost savings, with $5 million expected in 2025.

• Portfolio and cost actions expected to impact FY2025 EBITDA by $(30) million (nutraceuticals/other), $(20) million (price carryover), $(15) million (Avoca exit), and $(10) million (variable incentive reset).